ArticleNature communications2019

Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.

Matthew J Sale et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.